Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus

被引:33
|
作者
Hong, Ying [1 ]
Rohatagi, Shashank [2 ]
Habtemariam, Bahru [1 ]
Walker, Joseph R. [2 ]
Schwartz, Sherwyn L. [3 ]
Mager, Donald E. [1 ]
机构
[1] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Buffalo, NY 14260 USA
[2] Daiichi Sankyo Pharma Dev, Edison, NJ USA
[3] Diabetes & Glandular Dis Clin, San Antonio, TX USA
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2008年 / 48卷 / 06期
关键词
type 2 diabetes mellitus; metformin; pharmacokinetics; pharmacodynamics; mathematical modeling;
D O I
10.1177/0091270008316884
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The exposure-response properties of metformin were characterized in 12 subjects with type 2 diabetes mellitus. The time course of drug concentration and effects on fasting plasma glucose and lactic acid concentrations were used from a study in which subjects received 500 mg of metformin twice daily for 5 days followed by 850 mg twice daily for 5 days. Pharmacokinetic sampling included morning trough concentrations obtained on days 7 to 9 and rich sampling (15 time points) on day 10. Fasting plasma glucose and lactic acid concentrations were measured on days 0 to 10 and served as biomarkers of therapeutic effect and tolerability, respectively. A population pharmacokinetic/pharmacodynamic analysis was conducted using nonlinear mixed effects modeling. Metformin pharmacokinetics were described using a 1-compartment model with first-order absorption. Population mean estimates (relative standard error [RSE]) of clearance (CLIF) and volume of distribution were 79.0 L.h(-1) (6.8%) and 648 L (13.8%), respectively. Covariate analyses revealed that creatinine clearance (CLCR) significantly influenced metformin CLIF [CL/F = 79.0.(CLCR/80)(0.822)]. An indirect response model was applied to describe the antihyperglycemic effect of metformin. Population mean estimates (RSE) of baseline fasting plasma glucose and the drug concentration producing half-maximal effect were 241 mg.dL(-1) (4.6%) and 4.23 mg.L-1 (31.0%). An empirical linear model was used to describe a slight progressive increase in fasting lactic acid during metformin treatment with an estimated slope coefficient (RSE) of 0.0005 mM.mL.ng(-1) (38.1 %). Model evaluation by predictive check and non-parametric bootstrap analysis suggested that the proposed model is robust, and parameter values were estimated with good precision. Simulations suggested that the clinical utility of metformin was maintained over the dose range evaluated with respect to fasting plasma glucose and lactic acid response.
引用
收藏
页码:696 / 707
页数:12
相关论文
共 50 条
  • [1] Comparison of the Exposure-Response Relationship of Dapagliflozin in Adult and Pediatric Patients with Type 2 Diabetes Mellitus
    Parkinson, Joanna
    Tang, Weifeng
    Johansson, Carl-Christer
    Boulton, David W.
    Hamren, Bengt
    DIABETES, 2016, 65 : A337 - A337
  • [2] Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus
    Parkinson, J.
    Tang, W.
    Johansson, C-C.
    Boulton, D. W.
    Hamren, B.
    DIABETES OBESITY & METABOLISM, 2016, 18 (07): : 685 - 692
  • [3] Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
    Baron, Kyle T.
    Macha, Sreeraj
    Broedl, Uli C.
    Nock, Valerie
    Retlich, Silke
    Riggs, Matthew
    DIABETES THERAPY, 2016, 7 (03) : 455 - 471
  • [4] Population Pharmacokinetics of Metformin in Mexican Patients with Type 2 Diabetes Mellitus
    Barranco Garduno, L. M.
    Neri Salvador, J. C.
    Juarez Olguin, H.
    Lugo Goytia, G.
    Carrasco Portugal, M.
    Flores Murrieta, F.
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2015, 11 (06) : 632 - 637
  • [5] Population pharmacokinetics of metformin in obese patients with type 2 diabetes mellitus
    Bardin, C.
    Nobecourt, E.
    Larger, E.
    Chast, F.
    Treluyer, J.
    Urien, S.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 79 - 79
  • [6] Liraglutide pharmacokinetics and exposure-response in pediatric patients with type 2 diabetes
    Petri, Kristin C. C.
    Hale, Paula M.
    Hofman, Paul L.
    Jacobsen, Lisbeth, V
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2020, 33 (10): : 1289 - 1292
  • [7] Variability in the therapeutic response of Metformin treatment in patients with type 2 diabetes mellitus
    Rashid, Maryam
    Shahzad, Muhammad
    Mahmood, Saqib
    Khan, Khurshid
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2019, 35 (01) : 71 - 76
  • [8] Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus
    Kuan, Yi-Chun
    Huang, Kuang-Wei
    Lin, Cheng-Li
    Hu, Chaur-Jong
    Kao, Chia-Hung
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2017, 79 : 77 - 83
  • [9] Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus
    Li, Ling
    Guan, Ziwan
    Li, Rui
    Zhao, Wei
    Hao, Guoxiang
    Yan, Yan
    Xu, Yuedong
    Liao, Lin
    Wang, Huanjun
    Gao, Li
    Wu, Kunrong
    Gao, Yuxia
    Li, Yan
    MEDICINE, 2020, 99 (46) : E23212
  • [10] Population Approach for Exposure-Response Modeling of Golimumab in Patients With Rheumatoid Arthritis
    Hu, Chuanpu
    Xu, Zhenhua
    Zhang, Yi
    Rahman, Mahboob U.
    Davis, Hugh M.
    Zhou, Honghui
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (05): : 639 - 648